Tier 3 — preclinical

Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine

B Olsson, M Johansson, J Gabrielsson, P Bolme
Eur J Clin Pharmacol 1988 34(1):77-82

Bibliography

PubMed
PMID 3360052
DOI
10.1007/BF01061422
Funding
Funding disclosure was not located in the indexed record reviewed; consult the source publication for the full funding statement.
Competing interests
Competing-interest disclosure was not located in the indexed record reviewed; consult the source publication for the full declaration.

Study snapshot

DesignHuman oral-versus-intravenous pharmacokinetic study
ModelHuman
Sample6 healthy volunteers
Intervention200 mg intravenous NAC and 400 mg oral NAC
DurationAcute crossover pharmacokinetic sampling
EndpointsReduced NAC bioavailability; Total NAC bioavailability; Plasma concentrations

What the study showed, in plain terms

Classic study comparing oral and intravenous NAC while distinguishing reduced from total NAC-related species.

Key findings

Reported oral bioavailability was low, including roughly 4% for reduced NAC and about 9% for total NAC-related exposure.

What this study can and cannot tell us

Very small healthy-volunteer sample; older analytical methods and acute dosing.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology